SCHEMBL6284013

SCHEMBL6284013

CC(C)c1cnc(NC(=O)Nc2ccccc2C(=O)Nc2ccccc2)s1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 8/20 0.76
CCNE1 P24864 7/20 0.76
CDK5 Q00535 7/20 0.76
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
CCNT1 O60563 1/20 0.53
CDK1 P06493 1/20 0.53
CDK4 P11802 1/20 0.53
CCNB1 P14635 1/20 0.53
CCNA2 P20248 1/20 0.53
CCND1 P24385 1/20 0.53
CDK7 P50613 1/20 0.53
CDK9 P50750 1/20 0.53
CCNH P51946 1/20 0.53
MNAT1 P51948 1/20 0.53
CDK5R1 Q15078 1/20 0.53
CYP1A2 P05177 1/20 0.50
ALPL P05186 1/20 0.50
ALPI P09923 1/20 0.50
ALPG P10696 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284074 0.87 CDK2 (1.00) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL24072507 0.83 CDK2 (0.64) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL30142906 0.83 CDK2 (0.64) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5835764 0.82 CDK2 (0.66) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6281756 0.81 CDK2 (0.70) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6288105 0.80 CDK2 (0.69) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6756275 0.80 CCNE1 (0.50) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6288089 0.80 CDK2 (0.68) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6281642 0.80 CDK2 (0.68) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6177659 0.79 CDK2 (0.73) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
CN-1325390-A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2001-12-05 CN claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed
CN-1325390-A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2001-12-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CCNE1 83/4885CDK5 129/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CCNE1 83/4885CDK5 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.